Incidence of AQP4-IgG seropositive neuromyelitis optica spectrum disorders in the Netherlands: About one in a million
Author(s) -
E Daniëlle van Pelt,
Yu Yi M. Wong,
I. A. Ketelslegers,
Dorine A. M. Siepman,
Dörte Hamann,
Rogier Q. Hintzen
Publication year - 2016
Publication title -
multiple sclerosis journal - experimental translational and clinical
Language(s) - English
Resource type - Journals
ISSN - 2055-2173
DOI - 10.1177/2055217315625652
Subject(s) - neuromyelitis optica , incidence (geometry) , medicine , aquaporin 4 , spectrum disorder , population , immunology , myelitis , antibody , pediatrics , spinal cord , environmental health , psychiatry , physics , optics
Neuromyelitis optica (NMO) is a rare autoimmune disease affecting the optic nerves and spinal cord. In the majority of NMO patients anti-aquaporin-4 antibodies (AQP4-IgG) are detected. Here we assessed a nationwide incidence of AQP4-IgG-seropositive NMO spectrum disorders (NMOSD) in the Netherlands based on results of one central laboratory. Data were collected since the introduction of the highly sensitive cell-based assay for six consecutive years. Samples from 2795 individual patients have been received; of them 94 (3.4%) were seropositive. Based on the Dutch population with 16.6 million inhabitants, the mean incidence of AQP4-IgG-seropositive NMOSD was calculated at 0.09 per 100,000 people.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom